review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.2217/NNM.14.162 |
P698 | PubMed publication ID | 25490425 |
P2093 | author name string | Tariq M Rana | |
Huricha Baigude | |||
P2860 | cites work | Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development | Q21145874 |
Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54 | Q21146051 | ||
Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing | Q24537549 | ||
A microRNA expression signature of human solid tumors defines cancer gene targets | Q24541455 | ||
Identification of mammalian microRNA host genes and transcription units | Q24562298 | ||
Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP | Q24630900 | ||
MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis | Q24634064 | ||
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis | Q24634165 | ||
A mammalian microRNA expression atlas based on small RNA library sequencing | Q24644709 | ||
Widespread microRNA repression by Myc contributes to tumorigenesis | Q24647067 | ||
miRBase: tools for microRNA genomics | Q24649872 | ||
Suppression of non-small cell lung tumor development by the let-7 microRNA family | Q24651985 | ||
Most mammalian mRNAs are conserved targets of microRNAs | Q24655061 | ||
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model | Q24655262 | ||
Interferon modulation of cellular microRNAs as an antiviral mechanism | Q27489711 | ||
Mammalian microRNAs predominantly act to decrease target mRNA levels | Q27860535 | ||
Cellular microRNA and P bodies modulate host-HIV-1 interactions | Q37391014 | ||
Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif | Q37403837 | ||
In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle | Q37528689 | ||
Therapeutic Advances in MicroRNA Targeting | Q37781673 | ||
Analysis of microRNA knockouts in mice | Q37784095 | ||
MicroRNA therapeutics. | Q37869804 | ||
MicroRNA profiling in cancer | Q37869934 | ||
MicroRNAs and developmental timing | Q37870321 | ||
MicroRNA replacement therapy for cancer | Q37924177 | ||
Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. | Q38119269 | ||
PEI-complexed LNA antiseeds as miRNA inhibitors | Q38322616 | ||
MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. | Q38336334 | ||
A direct comparison of anti-microRNA oligonucleotide potency. | Q38344485 | ||
Substrate-mediated delivery of microRNA-145 through a polysorbitol-based osmotically active transporter suppresses smooth muscle cell proliferation: implications for restenosis treatment. | Q39004017 | ||
The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice | Q39025497 | ||
miR-TRAP: a benchtop chemical biology strategy to identify microRNA targets | Q39352122 | ||
Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. | Q39512199 | ||
MiR-33 contributes to the regulation of cholesterol homeostasis. | Q39704194 | ||
Specificity and functionality of microRNA inhibitors | Q39886691 | ||
siRNA function in RNAi: a chemical modification analysis | Q42044356 | ||
Single-stranded microRNA mimics | Q42125976 | ||
In Vivo Delivery of RNAi by Reducible Interfering Nanoparticles (iNOPs). | Q42848073 | ||
RNAi in human cells: basic structural and functional features of small interfering RNA. | Q44199577 | ||
Origins and Mechanisms of miRNAs and siRNAs | Q27860822 | ||
Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
Biogenesis of small RNAs in animals | Q27861013 | ||
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 | ||
Causes and consequences of microRNA dysregulation in cancer | Q28258994 | ||
let-7 regulates self renewal and tumorigenicity of breast cancer cells | Q28261263 | ||
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation | Q28268899 | ||
The let-7 microRNA reduces tumor growth in mouse models of lung cancer | Q28272817 | ||
MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis | Q28509140 | ||
MicroRNA discovery by similarity search to a database of RNA-seq profiles | Q28679161 | ||
Regulation of mRNA translation and stability by microRNAs | Q29547304 | ||
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting | Q29547487 | ||
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection | Q29615959 | ||
LNA-mediated microRNA silencing in non-human primates | Q29615962 | ||
Illuminating the silence: understanding the structure and function of small RNAs | Q29622905 | ||
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. | Q31967436 | ||
Emerging Roles for Natural MicroRNA Sponges | Q33805820 | ||
MicroRNA sponges: progress and possibilities | Q34139023 | ||
Targeting microRNAs in cancer: rationale, strategies and challenges | Q34141089 | ||
Chemical modification and design of anti-miRNA oligonucleotides. | Q34200255 | ||
miRNAs on the move: miRNA biogenesis and the RNAi machinery | Q34320973 | ||
Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. | Q34673364 | ||
Silencing microRNA by interfering nanoparticles in mice | Q34723841 | ||
Mammalian miRNA curation through next-generation sequencing | Q34917408 | ||
A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference | Q34919422 | ||
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. | Q35606800 | ||
Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs | Q35823712 | ||
Molecular mechanisms of RNA-triggered gene silencing machineries. | Q36099794 | ||
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia | Q36288982 | ||
Silencing of microRNA families by seed-targeting tiny LNAs | Q36522844 | ||
DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer | Q36676474 | ||
Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma | Q36901850 | ||
Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells. | Q36920080 | ||
Potent inhibition of microRNA in vivo without degradation | Q37041859 | ||
Inhibition of microRNA with antisense oligonucleotides | Q37044780 | ||
P433 | issue | 16 | |
P304 | page(s) | 2545-2555 | |
P577 | publication date | 2014-11-01 | |
P1433 | published in | Nanomedicine | Q15817508 |
P1476 | title | Strategies to antagonize miRNA functions in vitro and in vivo | |
P478 | volume | 9 |
Q51282064 | Assessing the Off-Target Effects of miRNA Inhibitors on Innate Immune Toll-Like Receptors. |
Q57022699 | Bone protection by inhibition of microRNA-182 |
Q49424922 | MicroRNAs and cancer: Key paradigms in molecular therapy |
Q57043965 | The Potential Roles of CircRNAs in Osteoarthritis: A Coming Journey to Find a Treasure |
Q92878849 | miRNAs and their roles in KSHV pathogenesis |
Search more.